Effectiveness of Palivizumab against Respiratory Syncytial Virus: Cohort and Case Series Analysis
Author:
Funder
Telethon Perth Children's Hospital Research Fund Application
National Health and Medical Research Council Fellowship
Publisher
Elsevier BV
Subject
Pediatrics, Perinatology, and Child Health
Reference27 articles.
1. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study;Shi;Lancet,2017
2. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants;Pediatrics,1998
3. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease;Feltes;J Pediatr,2003
4. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection;Pediatrics,2014
5. ADEC 231st meeting resolutions, 4-5 December;Australian Drug Evaluation Committee,2003
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Respiratory syncytial virus disease morbidity in Australian infants aged 0 to 6 months: a systematic review with narrative synthesis;BMC Public Health;2023-12-21
2. Respiratory Syncytial Virus disease morbidity in Australian infants aged 0 to 6 months: A systematic review and evaluation;2023-10-27
3. Determining the true incidence of seasonal respiratory syncytial virus-confirmed hospitalizations in preterm and term infants in Western Australia;Vaccine;2023-08
4. Health service utilisation for acute respiratory infections in infants graduating from the neonatal intensive care unit: a population-based cohort study;BMC Pediatrics;2023-07-01
5. Desenlaces clínicos generados por la infección del virus sincitial respiratorio durante los primeros dos años de vida en pacientes de un programa canguro que recibieron profilaxis completa con palivizumab. Estudio de cohorte retrospectivo;Pediatría;2023-03-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3